---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-002698"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:34:09.228443+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma Q3 net loss $3.9M; cash $31.3M; pipeline advances to Phase 3

## Summary
- Net loss $3.9M ($0.09 loss per share) vs $3.8M loss a year ago.
- Cash, equivalents and ST investments $31.3M as of Dec 31, 2022; funds operations into Q2 2024.
- GTX-104: Expects FDA Type C meeting in Q1 2023; may initiate Phase 3 safety study.
- GTX-102 PK bridging study met all primary endpoints; Phase 3 planning underway.
- GTX-101 PK study met all primary endpoints; multiple ascending dose study planned in 2023.

## SEC filing metadata
- accession: 0000950170-23-002698
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017023002698/0000950170-23-002698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017023002698/acst-20230214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-002698
- JSON: https://secwatch.observer/filing/0000950170-23-002698.json
- Plain text: https://secwatch.observer/filing/0000950170-23-002698.txt

## Key facts
- Earnings Releases
  Grace Therapeutics, Inc. reported financial results for the third quarter ended December 31, 2022.
  - Period: the third quarter ended December 31, 2022
  - Result: reported results
  source text: On February 14, 2023, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023002698/0000950170-23-002698-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.